相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。17-Allylamino-17-demethoxygeldanamycin loaded PCL/PEG nanofibrous scaffold for effective growth inhibition of T47D breast cancer cells
Sona Talaei et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2019)
Macrophage repolarization using emu oil-based electrospun nanofibers: possible application in regenerative medicine
Reza Zamani et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Watercress-based electrospun nanofibrous scaffolds enhance proliferation and stemness preservation of human adipose-derived stem cells
Mehdi Dadashpour et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
An in vitro examination of the antioxidant, cytoprotective and anti-inflammatory properties of chrysin-loaded nanofibrous mats for potential wound healing applications
Yaghoub Deldar et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells
Raana Farajzadeh et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art
Hassan Mellatyar et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Chrysin-nanoencapsulated PLGA-PEG for macrophage repolarization: Possible application in tissue regeneration
Akram Firouzi-Amandi et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting HSP90 gene expression
Hassan Mellatyar et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
A Biomimetic Emu Oil-Blended Electrospun Nanofibrous Mat for Maintaining Stemness of Adipose Tissue-Derived Stem Cells
Sepideh Jalilzadeh-Tabrizi et al.
BIOPRESERVATION AND BIOBANKING (2018)
A Biomimetic Emu Oil-Blended Electrospun Nanofibrous Mat for Maintaining Stemness of Adipose Tissue-Derived Stem Cells
Sepideh Jalilzadeh-Tabrizi et al.
BIOPRESERVATION AND BIOBANKING (2018)
Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed, in vitro, on Leishmania (L) amazonensis Amastigotes-Hosted in Mouse CBA Macrophages
Antonio Luis de Oliveira Almeida Petersen et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2018)
Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition
Mina Chatran et al.
DRUG RESEARCH (2018)
Development of quantum-dot-encapsulated liposome-based optical nanobiosensor for detection of telomerase activity without target amplification
Ali Zavari-Nematabad et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2017)
Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors
Elham Ajorlou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Triolimus: A Multi-Drug Loaded Polymeric Micelle Containing Paclitaxel, 17-AAG, and Rapamycin as a Novel Radiosensitizer
Keishiro Tomoda et al.
MACROMOLECULAR BIOSCIENCE (2017)
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
Arefeh Rouhi et al.
ONCOTARGET (2017)
Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy
Dae Hwan Shin et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation
Stefan Tukaj et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Synthesis of polymeric nano/microgels: a review
Yusof Bin Hamzah et al.
JOURNAL OF POLYMER RESEARCH (2017)
Co-Delivery of Curcumin and Chrysin by Polymeric Nanoparticles Inhibit Synergistically Growth and hTERT Gene Expression in Human Colorectal Cancer Cells
Javid Lotfi-Attari et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2017)
Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer
Bao Le et al.
PLOS ONE (2017)
Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
Helga Weber et al.
ONCOTARGET (2017)
Silibinin-loaded magnetic nanoparticles inhibit hTERT gene expression and proliferation of lung cancer cells
Soumaye Amirsaadat et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2017)
Development of Emu oil-loaded PCL/collagen bioactive nanofibers for proliferation and stemness preservation of human adipose-derived stem cells: possible application in regenerative medicine
Kazem Nejati-Koshki et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2017)
Antiproliferative and Apoptotic Effect of Dendrosomal Curcumin Nanoformulation in P53 Mutant and Wide-Type Cancer Cell Lines
Maryam Montazeri et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Hadi Sadeghzadeh et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
Antioxidant effects of chrysin-loaded electrospun nanofibrous mats on proliferation and stemness preservation of human adipose-derived stem cells
Yaghoub Deldar et al.
CELL AND TISSUE BANKING (2017)
Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma
R. Calero et al.
CANCER LETTERS (2017)
Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin
Biki Gupta et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
An update on application of nanotechnology and stem cells in spinal cord injury regeneration
Kazem Nejati-Koshki et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Spontaneous assembly of HSP90 inhibitors at water/octanol interface: A molecular dynamics simulation study
Amin Reza Zolghadr et al.
CHEMICAL PHYSICS LETTERS (2017)
Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential
Cun Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Upregulation of Mir-34a in AGS Gastric Cancer Cells by a PLGA-PEG-PLGA Chrysin Nano Formulation
Farideh Mohammadian et al.
Asian Pacific Journal of Cancer Prevention (2016)
Design and development of PCR-free highly sensitive electrochemical assay for detection of telomerase activity using Nano-based (liposomal) signal amplification platform
Mohammadreza Alizadeh-Ghodsi et al.
BIOSENSORS & BIOELECTRONICS (2016)
Jump in the fire - heat shock proteins and their impact on ovarian cancer therapy
M. B. Stope et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation
Ankit K. Rochani et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation
Kruti S. Soni et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition
Srikumar M. Raja et al.
ONCOTARGET (2016)
HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy
Tzu-yin Lin et al.
THERANOSTICS (2016)
Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin
Roshan Pradhan et al.
CARBOHYDRATE POLYMERS (2015)
Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice
Rui Yang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
Katrina S. Pedersen et al.
INVESTIGATIONAL NEW DRUGS (2015)
Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models
Swapnil S. Desale et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Topically Applied Hsp90 Inhibitor 17AAG Inhibits UVR-Induced Cutaneous Squamous Cell Carcinomas
Anupama Singh et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model
Yunze Xu et al.
TUMOR BIOLOGY (2015)
The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells
Hirokazu Hirakawa et al.
CANCER MEDICINE (2015)
17-AAG enhances the cytotoxicity of flavopiridol in mantle cell lymphoma via autophagy suppression
Y. Xiao et al.
NEOPLASMA (2015)
Comparison of Inhibitory Effect of 17-DMAG Nanoparticles and Free 17-DMAG in HSP90 Gene Expression in Lung Cancer
Hassan Mellatyar et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer
Masoud Gandomkar Ghalhar et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin- resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway
Takashi Ui et al.
ONCOLOGY REPORTS (2014)
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
Young Eun Choi et al.
ONCOTARGET (2014)
Passive targeting of nanoparticles to cancer: A comprehensive review of the literature
Remon Bazak et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Design and processing of nanogels as delivery systems for peptides and proteins
Laerke Arnfast et al.
THERAPEUTIC DELIVERY (2014)
Inhibitory Effects of β-Cyclodextrin-Helenalin Complexes on H-TERT Gene Expression in the T47D Breast Cancer Cell Line - Results of Real Time Quantitative PCR
Samaneh Ghasemali et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells
Jianjun Zhang et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2013)
Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme
Vipin Saxena et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2013)
The Therapeutic Target Hsp90 and Cancer Hallmarks
Yoshihiko Miyata et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Ying Lu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
Gnana Prakasam Krishnamoorthy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Zev A. Wainberg et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia
Alison R. Walker et al.
LEUKEMIA & LYMPHOMA (2013)
Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
Guanxiong Ding et al.
PLOS ONE (2013)
Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
Xiangyi Lu et al.
BIOCHEMICAL PHARMACOLOGY (2012)
The Effects of Heat Shock Protein 90 Inhibitors on Apoptosis and Viral Replication in Primary Effusion Lymphoma Cells
Chizuka Higashi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
Elaina M. Gartner et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
Bryan Newman et al.
CANCER RESEARCH (2012)
Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer
Vipin Saxena et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2012)
Paclitaxel-incorporated nanoparticles of hydrophobized polysaccharide and their antitumor activity
Sang Joon Lee et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey et al.
INVESTIGATIONAL NEW DRUGS (2012)
Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG
Jason R. Hasenstein et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
Katherine J. O'Malley et al.
PROSTATE (2012)
Liposomes and inorganic nanoparticles for drug delivery and cancer imaging
Carola Heneweer et al.
THERAPEUTIC DELIVERY (2012)
Nano Self-Assembly of Recombinant Human Gelatin Conjugated with α-Tocopheryl Succinate for Hsp90 Inhibitor, 17-AAG, Delivery
Young-Wook Won et al.
ACS NANO (2011)
Aggregation-enhanced fluorescence in PEGylated phospholipid nanomicelles for in vivo imaging
Dan Wang et al.
BIOMATERIALS (2011)
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
Scott H. Kaufmann et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin
Nate Larson et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Multi-drug delivery to tumor cells via micellar nanocarriers
Usha Katragadda et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Joleen Hubbard et al.
INVESTIGATIONAL NEW DRUGS (2011)
17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells
Panagiotis K. Karkoulis et al.
BMC CANCER (2010)
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
Srikumar M. Raja et al.
CANCER BIOLOGY & THERAPY (2010)
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
Ulka N. Vaishampayan et al.
CLINICAL CANCER RESEARCH (2010)
Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG)
Thripthy Chandran et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells Laboratory investigation
Shigeo Ohba et al.
JOURNAL OF NEUROSURGERY (2010)
MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells
Tao Zhang et al.
MOLECULAR PHARMACEUTICS (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Targeting Heat Shock Protein 90 Overrides the Resistance of Lung Cancer Cells by Blocking Radiation-Induced Stabilization of Hypoxia-Inducible Factor-1α
Woo-Young Kim et al.
CANCER RESEARCH (2009)
HSP90 is essential for Jak-STAT signaling in classical Hodgkin Lymphoma cells
Nils Schoof et al.
CELL COMMUNICATION AND SIGNALING (2009)
17 AAG for HSP90 Inhibition in Cancer - From Bench to Bedside
Saad Z. Usmani et al.
CURRENT MOLECULAR MEDICINE (2009)
Folate-targeted therapeutic and imaging agents for cancer
Philip Stewart Low et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
Charles Erlichman
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: A novel targeted nanomedicine for breast cancer
Hayat Oenyueksel et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs
Ho-Chul Shin et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation
Cinzia Fionda et al.
JOURNAL OF IMMUNOLOGY (2009)
A Cremophor-Free Formulation for Tanespimycin (17-AAG) Using PEO-b-PDLLA Micelles: Characterization and Pharmacokinetics in Rats
May P. Xiong et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Claire Marie-Elisabeth Sauvageot et al.
NEURO-ONCOLOGY (2009)
17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis
Markus David Siegelin et al.
NEUROBIOLOGY OF DISEASE (2009)
Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P-berghei-infected mice
Matheus Santos de Sa et al.
PARASITOLOGY RESEARCH (2009)
Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
Matthew M. Roforth et al.
ANTI-CANCER DRUGS (2008)
Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling
Laila Al Shaer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models
Udai Banerji et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells
Esther P. Jane et al.
CANCER LETTERS (2008)
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
David B. Solit et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath et al.
CLINICAL CANCER RESEARCH (2008)
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2008)
17-Allylamino-17-Demethoxygeldanamycin Down-Regulates Hyaluronic Acid-Induced Glioma Invasion by Blocking Matrix Metalloproteinase-9 Secretion
Mi-Suk Kim et al.
MOLECULAR CANCER RESEARCH (2008)
Cisplatin abrogates the geldanamycin-induced heat shock response
Andrea K. McCollum et al.
MOLECULAR CANCER THERAPEUTICS (2008)
HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells
Paul N. Meyer et al.
LEUKEMIA RESEARCH (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hsp90 - From signal transduction to cell transformation
Mark A. Brown et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines
P. Garcia-Morales et al.
ONCOGENE (2007)
Intratumor injection of the hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
Christopher R. Williams et al.
JOURNAL OF UROLOGY (2007)
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
Ramesh K. Ramanathan et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B. Solit et al.
CLINICAL CANCER RESEARCH (2007)
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: A children's oncology group study
Brenda J. Weigel et al.
CLINICAL CANCER RESEARCH (2007)
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors:: A pediatric oncology experimental therapeutics investigators consortium study
Rochelle Bagatell et al.
CLINICAL CANCER RESEARCH (2007)
Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl-amino-17-demethoxy analogue
A. Pataer et al.
CANCER GENE THERAPY (2007)
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
Ellen A. Ronnen et al.
INVESTIGATIONAL NEW DRUGS (2006)
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer
Grzegorz S. Nowakowski et al.
CLINICAL CANCER RESEARCH (2006)
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9
Georgios V. Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
Sebastian Bauer et al.
CANCER RESEARCH (2006)
Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma
J. Duus et al.
LEUKEMIA & LYMPHOMA (2006)
The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level
WJ Yu et al.
LEUKEMIA RESEARCH (2006)
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
M Senju et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Heat shock proteins in cancer: chaperones of tumorigenesis
SK Calderwood et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Antimyeloma activity of heat shock protein-90 inhibition
CS Mitsiades et al.
BLOOD (2006)
17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear Factor-κB pathway
X Wang et al.
CANCER RESEARCH (2006)
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death
GV Georgakis et al.
CLINICAL CANCER RESEARCH (2006)
Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive
Gabriela Chiosis et al.
ACS CHEMICAL BIOLOGY (2006)
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
U Banerji et al.
CLINICAL CANCER RESEARCH (2005)
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia
JE Castro et al.
BLOOD (2005)
17-allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines
IA Vasilevskaya et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models
V Smith et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
T Shimamura et al.
CANCER RESEARCH (2005)
Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-emethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
RK Ramanathan et al.
CLINICAL CANCER RESEARCH (2005)
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity
LM Hawkins et al.
PEDIATRIC RESEARCH (2005)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
AM Burger et al.
ANTI-CANCER DRUGS (2004)
Targeting multiple signal transduction pathways through inhibition of Hsp90
H Zhang et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2004)
Hsp90: an emerging target for breast cancer therapy
J Beliakoff et al.
ANTI-CANCER DRUGS (2004)
Targeted liposomal drug delivery in cancer
OP Medina et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
17-allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels
M Braga-Basaria et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3
P George et al.
CANCER RESEARCH (2004)
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
SJH Arlander et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Regulation of survivin function by Hsp90
P Fortugno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
YL Chung et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Hsp90 as a therapeutic target in prostate cancer
DB Solit et al.
SEMINARS IN ONCOLOGY (2003)
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways
WT Jia et al.
BLOOD (2003)
Regulation of 17-AAG-induced apoptosis:: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases
R Nimmanapalli et al.
BLOOD (2003)
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells
R Villa et al.
CARCINOGENESIS (2003)
Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects
NC Santos et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Edward A. Sausville et al.
CURRENT CANCER DRUG TARGETS (2003)
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
AD Basso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
ME Gorre et al.
BLOOD (2002)
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
JS Isaacs et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
AD Basso et al.
ONCOGENE (2002)
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: In vitro and in vivo analysis
DM Nguyen et al.
ANNALS OF THORACIC SURGERY (2001)
Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability
G de Cárcer et al.
EMBO JOURNAL (2001)
Stable association of hsp90 and p23, but not hsp70, with active human telomerase
HL Forsythe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90
WP Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Biodegradable polymeric nanoparticles as drug delivery devices
KS Soppimath et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Modulation of Akt kinase activity by binding to Hsp90
S Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone
PA Clarke et al.
ONCOGENE (2000)
Control of estrogen receptor ligand binding by Hsp90
AE Fliss et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2000)
分享论文
